Closing in on treatment for Charcot-Marie-Toot...( other proteins and protecting against ...)

Closing in on treatment for Charcot-Marie-Tooth disease?

other proteins and protecting against degradation. The specific function of the two HSPs in our peripheral nerves has not yet become clear, but the mutations that have been discovered in several European families are now leading to serious symptoms.

Toward new therapies

The scientists have shown that the mutations lead to a stronger interaction between the two HSPs. This causes a precipitation in cultured cells and reduces the viability of neurons. These findings demonstrate the importance of HSPs in neurodegenerative disorders. The team's research results will open the way for new progress in the development of therapies for these hereditary nervous disorders. These HSPs have previously been studied in Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease), a serious acquired disorder of the nervous system. Hopefully, the discovery of the mutations in the two HSPs will now lead to new insights into this disorder as well.

'"/>

Contact: Ann Van Gysel
ann.vangysel@vib.be
32-9-244-6611
VIB, Flanders Interuniversity Institute of Biotechnology
7-May-2004

Page: 1 2
Related biology news :

1. Closing in on the cellular culprits of schizophrenia
2. Researchers Closing In On Gene For Paralytic Disorder
3. Leader in cancer treatment and prevention research honored
4. International study findings link acne-like rash to effectiveness of new targeted cancer treatment
5. New study indicates arsenic could be suitable as first-line treatment in type of leukaemia
6. New treatment for fibromyalgia
7. The impact of genetic variations on the treatment of early rheumatoid arthritis
8. OneWorld Health compiles comprehensive state of infectious diarrhea treatments, potential solutions
9. Early clinical treatment can halt progression of Alzheimers disease, UCI researchers find
10. Colleagues to recognize research leadership in cancer detection, prevention and treatment
11. New view of leukemia cells identifies best treatment options, Stanford researchers say

Post Your Comments:

(Date:11/22/2009)...team of pioneering South Korean scientists have su...y plastics through bioengineering, rather than thr...groundbreaking research, which may now allow for t...s, is published in two papers in the journal Biot...s 50th anniversary. , Polymers are molecules fo...

(Date:11/22/2009)...Cambridge, MA November 23, 2009 Agios Pharmaceut...ablished, for the first time, that the mutated IDH... a cancer-causing gene, or oncogene. This breakthr... produces a metabolite, 2-hydroxyglutarate (2HG), ...t progression of gliomas, the most common type of ...

(Date:11/20/2009)... a research report published in the November 2009 ...ics.org ), scientists show how a family of genes (... genes) are responsible for production of ethylene...nt, and this information lays the foundation for f...disease resistant, able to survive and thrive in d...

Breaking Biology News(10 mins):Bioengineers succeed in producing plastic without the use of fossil fuels 2 Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 2 Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 3 Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 4 It's a gas: New discovery may lead to heartier, high-yielding plants 2 Hologic to Release Fourth Quarter and Fiscal 2009 Operating Results on Monday November 9 2009 58885 1 Hologic to Release Fourth Quarter and Fiscal 2009 Operating Results on Monday November 9 2009 58885 2 Hanger Orthopedic Group Inc Announces Third Quarter 2009 Earnings Release Conference Call 58881 1 Hanger Orthopedic Group Inc Announces Third Quarter 2009 Earnings Release Conference Call 58881 2 ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema 28MIVI II DME 29 14355 1 ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema 28MIVI II DME 29 14355 2 ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema 28MIVI II DME 29 14355 3 ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema 28MIVI II DME 29 14355 4

[3] Bioengineers succeed in producing plastic without the use of fossil fuels [0] Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer [0] It's a gas: New discovery may lead to heartier, high-yielding plants

(Date:11/20/2009)...Newswire/ -- Veridiam (www.veridiam.com) won the p...ategory at the 2009 Workplace Excellence Awards. T...or Human Resources Management and recognize innova..., Veridiam was one of nine winners, selected fro...red at the recent awards ceremony. San Diego-based...

(Date:11/20/2009)...PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (...he Ninth Circuit Court of Appeals reversed a U.S. ...allowed to pursue all of its claims against The La...urt for trial. CTI filed a complaint against The ... consultant for CTI,s product TRISENOX, in 2007 se...

(Date:11/19/2009)...Newswire/ -- Danish Prince Joachim inaugurated the...in Kalundborg, Denmark, on Wednesday, November 18....est 2nd generation ethanol demonstration biorefine...he plant,s innovative process for converting straw... first to market with commercial enzymes for conve...

(Date:11/19/2009)...ewswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex: N...ng letter to its shareholders, discussing the Comp...iopharmaceuticals Holdings, Inc. (CHBP), an integr...e,s Republic of China. The merger gives NeoStem a ...ical Co. Ltd., CHBP,s primary operating subsidiary...

Breaking Biology Technology:Veridiam Wins Workplace Excellence Crystal Award in Mid-Size Company Category 2 Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group 2 DONG Energy and Inbicon Inaugurate One of the World's Largest Demo Plants for 2nd Generation Biofuel 2 NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2 NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3

[1] Veridiam Wins Workplace Excellence Crystal Award in Mid-Size Company Category [0] Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group [0] DONG Energy and Inbicon Inaugurate One of the World's Largest Demo Plants for 2nd Generation Biofuel [0] NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company

Other News:

. COLUMBUS, Ohio -- Researchers at Ohio State University. have taken the first step toward differentiating human cells in an. artificial gro

. Washington, D.C.- Americans for Medical Progress will present Albert.B. Sabin Heroes of Science Awards to six individuals who have made a.difference in biomedical research-pioneers in vaccine develo

... 2000 -- AVAX Technologies, Inc. (NASDAQ: AVXT) to...VAX Australia Pty. Ltd. has received an additional...national Holdings Limited (NIHL), which was recent...VT). AVAX Australia holds the rights to manufactu...

...essor of mathematics and codirector of the Center ...rsity's first William Goodwin Aurelio Professor of... her occupy this new professorship in the College ...ity Provost and Dean of the College of Arts and Sc...

Researchers find key to growing, differentiating human cells 2 Researchers find key to growing, differentiating human cells 3 Researchers find key to growing, differentiating human cells 4 Researchers find key to growing, differentiating human cells 5 Scientists, research advocates honored as Albert B. Sabin Heroes of Science 2 Scientists, research advocates honored as Albert B. Sabin Heroes of Science 3 AVAX Technologies receives an additional $3.0 Million (AUD) investment in Australian joint venture from Australian Vaccine Technologies Ltd. 2 Biomathematician named first Aurelio professor of mathematics and science at Boston University 2

Researchers find key to growing, differentiating human cells Scientists, research advocates honored as Albert B. Sabin Heroes of Science AVAX Technologies receives an additional $3.0 Million (AUD) investment in Australian joint venture from Australian Vaccine Technologies Ltd.Biomathematician named first Aurelio professor of mathematics and science at Boston University

...tmayr and a team from the School of Biological Sci...ration with scientists from Belgium, Germany, Norw...cted rise in climate temperature for the UK and pa...in the country's lakes and ponds.......The project...

...ng to the sweet lure of chocolate or the bitter ta...ehavioral responses be so innate as to be hard-wir...ily manipulable fruit fly Drosophila, Kristin Scot... issue of Neuron experiments demonstrating just su...

...e United States Pharmacopeia--the official public ...nd over-the-counter medicines and other health car...tes--demonstrates just how safe nuclear medicine p...er of errors voluntarily reported for nuclear medi...

...y (Nature, 12 January 2006), scientists from the M...niversity, Netherlands, and the Department of Agri..., UK, revealed that plants produce the greenhouse ...ould account for a significant proportion of metha...

Europe's largest climate change experiment launched 2 How taste response is hard-wired into the brain 2 Report demonstrates safety of nuclear medicine procedures 2 Report demonstrates safety of nuclear medicine procedures 3 Global warming - the blame is not with the plants 2

Europe's largest climate change experiment launched How taste response is hard-wired into the brain Report demonstrates safety of nuclear medicine procedures Global warming - the blame is not with the plants